AML patients with epigenetic modification gene ASXL1 mutations, considered an independent predictor of a poor outcome, affect 5-11% of AML patients and are especially common in older, male and secondary AML patients (37–39). The gene discussed is ASXL1; the disease is acute myeloid leukemia.